Validity of Mediastinal Blood Pool SUV Ratio
Is Mediastinal Blood Pool SUV Ratio Valid in Identification of Malignancy in Comparison to Liver SUV Ratio?
1 other identifier
observational
55
0 countries
N/A
Brief Summary
-Validity of blood pool SUV ratio in identification of malignancy in case of diseased liver.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2022
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 22, 2022
CompletedFirst Posted
Study publicly available on registry
February 28, 2022
CompletedStudy Start
First participant enrolled
June 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2023
CompletedFebruary 28, 2022
February 1, 2022
1.3 years
February 22, 2022
February 22, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
-Validity of blood pool suv ratio in identification of malignancy in case of diseased liver.
PET/CT is the functional imaging tool that can measure increased glucose metabolism in cancer tissues by using flourine 18 FDG which is FDA approved and used routinely in identification of malignant lesions , staging and restaging of many maligancy like lymphoma, breast cancer, lung cancer and cancer colon. In clinical routine, SUV is often used to determine the glucose metabolism in tumours by 18F-FDG PET/CT. And can be further normalised to SUVs in reference regions resulting in a SUV ratio (SUV ratio).in routine work SUV of the lesion is normalised to SUV of the liver , but this not used if the liver is diseased like as liver cirrhosis or liver metastases , so SUV ratio of lesion to mediastinal blood pool and SUV ratio of the lesion to liver will be measured in correlation to pathology to assess validity of SUV of mediastinal blood pool.
One year
Study Arms (1)
SUV ratio of mediastinal blood pool to the lesion and SUV ratio of liver to lesion
Avidity of SUV of blood pool
Interventions
Radioactive material
Eligibility Criteria
Cross sectional study prospective and retrospective
You may qualify if:
- This study will include cancer pt who did PET/CT scan who presented to nuclear medicine unit during the period from 2021 until the end of the study.
You may not qualify if:
- Severely ill patient
- Pt with glucose level above 200
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident doctor
Study Record Dates
First Submitted
February 22, 2022
First Posted
February 28, 2022
Study Start
June 1, 2022
Primary Completion
September 1, 2023
Study Completion
December 30, 2023
Last Updated
February 28, 2022
Record last verified: 2022-02